Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial
Fernando Rivera, Marta Izquierdo-Manuel, Pilar García‐Alfonso, Eva Martínez de Castro, Javier Gállego, María Luisa Limón, María Alsina, L. López, Maica Galán, E. Falcó, José Luís Zamora Manzano, Encarnación González‐Flores, Nerea Muñoz-Unceta, Carlos López, Enrique Aranda, Eva Fernández, Mónica Jorge, Paula Jiménez‐Fonseca
Topics & Concepts
MedicineCapecitabineOxaliplatinPerioperativeInternal medicineSurgeryTrastuzumabGastroenterologyClinical endpointChemotherapyPhases of clinical researchAdenocarcinomaCancerPopulationNauseaClinical trialColorectal cancerBreast cancerEnvironmental healthGastric Cancer Management and OutcomesHER2/EGFR in Cancer ResearchEsophageal Cancer Research and Treatment